Phase I/II Study of PS-341 in Combination With Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

Phase I/II Study of PS-341 in Combination With Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-Small Cell Lung Cancer (NSCLC).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Sep 2014

At a glance

  • Drugs Bortezomib (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jun 2012 Planned end date changed from 1 Aug 2005 to 1 Jan 2012 as reported by ClinicalTrials.gov.
    • 31 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 01 Feb 2008 Status changed from recruiting to suspended, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top